drugset / Trial / NCT00004779

Phase I Pilot Study of Ad5-CB-CFTR, an Adenovirus Vector Containing the Cystic Fibrosis Transmembrane Conductance Regulator Gene, in Patients With Cystic Fibrosis

NCT00004779 ↗

Treatment

Summary

OBJECTIVES: I. Assess the safety and efficacy of gene transfer into the nasal epithelium using Ad5-CB-CFTR, an E1-deleted adenovirus vector containing the cystic fibrosis transmembrane conductance regulator gene, in patients with cystic fibrosis (CF). II. Determine whether ion transport abnormalities in CF airway cells can be corrected.

Timeline

Start
1993-01
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad5-CB-CFTR Unknown — Intranasal

Indications